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Mycetoma is a chronic granulomatous subcutaneous inflammatory disease, caused by 108 certain bacteria (actinomycetoma) or fungi (eumycetoma). This infection progresses to affect pre-existing Th2 environment caused by schistosomiasis promotes the development of 140 mycetoma as patients with mycetoma were significantly more positive for schistosoma 141 antibodies than healthy endemic controls [9] . These findings suggested that Th2 like 142 response and anti-inflammatory/immunosuppressive cytokines could have a negative impact 143 on mycetoma development and disease progression.
144
IL-1 is a polypeptide which has two forms; IL-1α and IL-1β. It is involved in the acute-phase 145 response and is accountable for several alterations that are related to the onset of various 146 medical disorders [15, 16] . It is demonstrated recently that higher levels of IL-1β cytokine 147 are strongly associated with surgically treated mycetoma patients, in comparison to those 148 treated without surgery [17] . It is known that IL-1β is a pro-inflammatory cytokine that is 149 involved in cell death coordination [18] . IL-1β cytokine is cleaved into the mature, active (Table 2) . On the other hand, the 287 levels of cytokine IL-1β were constitutively negatively correlated with IL-37 and IL-35, (Table   288 2). Furthermore, the levels of cytokine IL-37 were constitutively positively correlated with IL-289 35 (Table 2) . However, the levels of cytokine IL-37 and IL-35 were constitutively negatively 290 correlated with IL-12 (Table 2) . (Table 3) . Whereas, levels of IL-37 were constitutively positively correlated with IL-35 (Table 12, (Table 3) .
301
Analysis of the serum levels of IL-1β, IL-37, IL-12 and IL-35 within the different lesion 302 diameters among mycetoma patients and control groups 303 Circulating serum cytokine levels were determined in all mycetoma patients and were 304 compared between the different lesion diameters among mycetoma patients and healthy 305 controls. Overall, there was a significant difference in the levels of all studied cytokines 306 between the four groups (Three levels of lesion diameter and the healthy controls), (Table
Risk factors for circulating IL-35 among mycetoma patients.
375
The analysis of the risk factors of higher levels of IL-35 in patients of mycetoma revealed a 376 significant negative association with IL-12; as a unit increment in IL-12 decreases the levels 377 of IL-35 by 8.99 pg/ml, p-value < 0.001 (Table 9 ). Levels of IL-35 among the patients with a 378 mycetoma with a disease duration of ≤ 1 year had significantly decreased, p value= 0.002), 379 on average by 41.82 pg/ml compared to patients with a disease duration ≥ 5years 380 (reference group) (Table 9 ). However, patients with an infection duration of 2-4 years and ≥ 381 five years showed no significant difference in IL-35 levels, p-value = 0.391. Furthermore,
382
there was no significant difference (p-value = 0.49) in IL-35 levels between male and female 383 mycetoma sufferers (Table 9) . Additionally, the circulating levels of IL-35 showed no 384 significant association with the different age groups (Table 9) . Interestingly, treatment with
385
Itraconazole significantly increased circulating levels of IL-35 among mycetoma patients 386 compared to treatment with Ketoconazole, p-value <0.001, (Table 9) . Caspase-8 modulates dectin-1 and complement receptor 3-driven IL-1beta 575 production in response to beta-glucans and the fungal pathogen, Candida albicans. 
